Weijian Pharma Resubmits Hong Kong Listing Application with 27 Marketed Drugs on June 25

According to Hong Kong Exchanges and Clearing disclosure on June 25, Weijian International Holdings submitted a main board listing application to HKEX, marking its second submission. Huatai International is the sole sponsor. The company's product portfolio comprises 27 commercialized drugs and 1 newly approved drug, covering kidney disease, blood disorders, respiratory and skin conditions.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments